Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.5mL Intramuscular Injection Clear all
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

NCT00328107
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccine, recombinant Hemagglutinin
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
18 Years to 49 Years
Enrollment
459 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
3
States / cities
Rochester, New York • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Oct 18, 2026, 9:05 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Phase I/II Study to a Assess the GBS-06 Vaccine Manufactured by Inventprise, Inc., in Healthy, Non-Pregnant, Adult Women of Childbearing Age.

NCT06611371
View directory record Official record
Conditions
Group B Streptococcal Infections
Interventions
IVT GBS-06, Placebo
Biological
Lead sponsor
Inventprise Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy

NCT01475786
View directory record Official record
Conditions
Painful Diabetic Neuropathies
Interventions
Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline)
Biological · Other
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Walnut Creek, California • Orlando, Florida • Palm Beach Gardens, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Completed No phase listed Observational

Safety Surveillance After Immunization With IXIARO

NCT01335412
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Japanese Encephalitis Virus vaccine, inactivated, adsorbed
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
17 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Cognitive, Emotional, and Neural Responses to Acute Inflammation

NCT03294564
View directory record Official record
Conditions
Healthy
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 18, 2026, 9:05 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine

NCT05293665
View directory record Official record
Conditions
COVID-19 Vaccines
Interventions
UB-612, BNT162b2 vaccine, ChAdOx1-S vaccine, Sinopharm BIBP
Biological
Lead sponsor
Vaxxinity, Inc.
Industry
Eligibility
16 Years and older
Enrollment
944 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Brownsville, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

NCT03104075
View directory record Official record
Conditions
Pneumonia, Aging
Interventions
Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Not applicable Interventional Results available

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

NCT00941889
View directory record Official record
Conditions
HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions
Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age

NCT02285998
View directory record Official record
Conditions
Influenza
Interventions
Flublok Quadrivalent Influenza Vaccine, Inactivated Influenza Vaccine
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
50 Years and older
Enrollment
9,003 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Tempe, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2017 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 2 Interventional

Evaluating New Formulation of Therapeutic HSV-2 Vaccine

NCT02515175
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
Matrix-M2, GEN-003, Placebo
Biological · Drug
Lead sponsor
Genocea Biosciences, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Inflammation and Threat Sensitivity in PTSD

NCT03048929
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease

NCT00829595
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn Disease, Ulcerative Colitis
Interventions
23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)
Biological
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2009 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations

NCT02100436
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 17 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Results available

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

NCT01349569
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Allogeneic Myeloma Vaccine, Prevnar-13
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Oct 18, 2026, 9:05 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age

NCT07365826
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,390 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Fort Collins, Colorado • DeLand, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 18, 2026, 9:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Gardasil Immunogenicity With Needle-Free Injection

NCT01924754
View directory record Official record
Conditions
HPV Seroconversion
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment

NCT06391125
View directory record Official record
Conditions
Syphilis Infection, Benzathine Penicillin Adverse Reaction
Interventions
normal Saline, Lidocaine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

RSV-F Vaccine Dose Ranging Study in Young Women

NCT01704365
View directory record Official record
Conditions
Respiratory Syncytial Virus (RSV)
Interventions
Low dose RSV-F Vaccine with Adjuvant, Low dose RSV-F Vaccine without Adjuvant, High dose RSV-F Vaccine with Adjuvant, High dose RSV-F Vaccine without Adjuvant, Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing], Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Anaheim, California • Rockville, Maryland • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 4 Interventional Results available

Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?

NCT01101750
View directory record Official record
Conditions
Cervical Cancer, Hpv, Warts
Interventions
Quadrivalent HPV for types 6, 11, 16 and 18
Biological
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
9 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

NCT02718469
View directory record Official record
Conditions
Ebola Virus Disease
Interventions
Ebola Vaccine - low dose, Ebola Vaccine - mid dose, Ebola Vaccine - high dose, Placebo
Biological
Lead sponsor
Auro Vaccines LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 18, 2026, 9:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Gardasil Vaccination in Post Stem Cell Transplant Patients

NCT01092195
View directory record Official record
Conditions
Gardasil Vaccine, Stem Cell Transplant, Immunogenicity
Interventions
Gardasil
Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 50 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Oct 18, 2026, 9:05 AM EDT
Recruiting Phase 1 Interventional

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

NCT04843852
View directory record Official record
Conditions
Hepatitis B, Chronic Hepatitis B
Interventions
Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B]
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 18, 2026, 9:05 AM EDT
Not listed No phase listed Observational

Proteomics & Glyco-Proteomic Analysis of Follicular Fluid

NCT01487486
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Normal Volunteers
Interventions
IVF Antagonist Protocol
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2011 · Synced Oct 18, 2026, 9:05 AM EDT
Active, not recruiting Phase 2 Interventional

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

NCT03519464
View directory record Official record
Conditions
Idiopathic CD4 T Cell Lymphocytopenia
Interventions
Gardasil 9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 18, 2026, 9:05 AM EDT